Several cardiovascular (CV) risk factors may pose high rate of death among patients with chronic kidney disease (CKD). Statin therapy significantly reduces cholesterol synthesis and both CV morbidity and mortality by reducing the lipid profile, or via pleiotropic effects. In fact, it is supposed to be able to reduce both the progression of CKD and also proteinuria. The incidence of chronic kidney disease (CKD) is rapidly increasing all over the world.
The reduction of CV risk factors remains a cornerstone of the treatment of patients affected by CKD who, up to 50% of the time, die of CV causes, before reaching the need for dialysis. Dyslipidemia plays an important role in CKD as it promotes atherosclerosis by the deposition of lipoprotein in glomerular structures, stimulates factors that excite inflammation and fibrogenesis. The safety of statins is demonstrated in CKD by several trials…
